Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare
GeneDx has officially appointed Dr. Linda Genen, MD, MPH as Chief Medical Officer. The appointment marks a strategic pivot for the genomic pioneer as it looks to transition from a specialized diagnostics lab into a foundational pillar of routine clinical care in 2026.
The Strategic Mandate: Scaling Beyond the Lab
Dr. Genen’s role is uniquely positioned at the intersection of clinical excellence and insurance viability. Her core responsibilities include:
-
Payer Strategy: Leveraging her background at UnitedHealth Group and Optum to secure broader reimbursement for whole genome sequencing (WGS).
-
Clinical Integration: Accelerating the adoption of genomics in NICU and pediatric settings to end the “diagnostic odyssey” for rare disease families.
-
Real-World Evidence: Utilizing the GeneDx Infinity™ dataset the world’s largest rare disease genomic database to prove long-term cost savings to health systems and policymakers.
Also Read: Nona Biosciences Names Dr. Hongjiang Miao Chief AI Officer for A³ Strategy
A Deep Pedigree in Maternal-Infant Health
Dr. Genen joins GeneDx from ProgenyHealth, where she served as CMO and led clinical strategy for maternity and NICU care management. Her career spans:
-
Neonatology: Practicing at Northwell’s Cohen Children’s Hospital.
-
Healthcare Innovation: Developing scaled women’s health models at Optum R&D.
-
Informatics Leadership: Serving as a Distinguished Mentor in Stanford’s Clinical Informatics Management program.
“By incorporating exome and genome testing at the earliest moment possible, we can transform our approach to healthcare from reactive to proactive,” said Katherine Stueland, CEO of GeneDx.
The 2026 Genomic Inflection Point
The hiring of Dr. Genen is a clear signal to the market that GeneDx is solving for the “Adoption Gap.” While the science of WGS is settled, the bottleneck remains payer skepticism and provider education. With 80% of covered lives already under contract and revenue projected to hit $428M in 2026, Dr. Genen’s expertise in “value-based care” will be the primary engine driving the company toward GAAP profitability.
Source: Businesswire
